Abstract
Background Evidence from one trial in Africa suggests that pre-referral Rectal Artesunate (RAS) can be a life-saving intervention for severe malaria in remote settings, where parenteral treatment is not available. Recognition of danger signs indicative of severe malaria is critical for prompt and appropriate case management.
Methods An observational study was conducted in the Democratic Republic of the Congo (DRC) in the frame of the multi-country CARAMAL project, to assess the effectiveness of RAS under real-world conditions. Severely ill feverish children <5 years seeking care from a community-based healthcare provider were recruited in three rural health zones into a patient surveillance system. They were subsequently followed within the healthcare system and at home after 28 days to determine care seeking, antimalarial treatment provision and health outcomes.
Results Overall, 66.4% of patients had iCCM general danger signs, as well as more specific danger signs. Children aged 2-5 years (aOR=1.58, 95% CI 1.20–2.08) and those presenting iCCM general danger signs were more likely to receive RAS (aOR = 2.77, 95% CI 2.04–3.77). Injectable treatment was less likely with RAS pre-referral treatment (aOR=0.21, 95% 0.13– 0.33). In the post-RAS phase, the case fatality ratio was 7.1%. Children not receiving RAS had a higher risk of dying, but this was not statistically significant (aOR = 1.50, 95% CI 0.86– 2.60). The odds of dying were reduced in patients without iCCM general danger signs, but just not statistically so (aOR = 0.64, 95% CI 0.38–1.06). Full oral therapy at a RHF was highly protective (aOR = 0.13, 95% CI 0.07-0.26), while a full treatment of severe malaria (injectable + oral) was shown to also decrease massively the odds of dying (aOR = 0.26, 95% CI 0.09– 0.79) compared to injectable treatment alone.
Conclusions Better understanding the determinants of successful case management, and targeted improvements of the health system (especially the provision of a full course of an oral antimalarial) are crucial for improving health oucomes of children with suspected severe malaria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The CARAMAL Project was funded by Unitaid (grant reference XM-DAC-30010-CHAIRAS). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CARAMAL study protocol was approved by the Research Ethics Review Committee of the World Health Organization (WHO ERC, No. ERC.0003008), the Ethics Committee of the University of Kinshasa School of Public Health (No. 012/2018), the Health Research Ethics Committee of the Adamawa State Ministry of Health (S/MoH/1131/I), the National Health Research Ethics Committee of Nigeria (NHREC/01/01/2007-05/05/2018), the Higher Degrees, Research and Ethics Committee of the Makerere University School of Public Health (No. 548), the Uganda National Council for Science and Technology (UNCST, No. SS 4534), and the Scientific and Ethical Review Committee of CHAI (No. 112, 21 Nov 2017). The study is registered on ClinicalTrials.gov (NCT03568344). Consent was obtained in a two-step process given that the enrolled children were medical emergencies: a first provisional oral consent was obtained at the point of recruitment. The final written informed consent was then obtained during the first contact of the patient/caretaker with the study team - at the referral facility or during the day-28 home visit.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
List of abbreviations
- 95% CI
- 95% Confidence Intervals
- ACT
- Artemisinin-based Combination Therapy
- aOR
- adjusted Odds Ratio
- CARAMAL
- Community Access to Rectal Artesunate for Malaria
- CFR
- Case Fatality Ratio
- CHCS
- Community Health Care Site
- CHW
- Community Health Worker
- DHS-DRC II
- DRC second Demographic and Health Survey
- DRC
- Democratic Republic of the Congo
- Hb
- Haemoglobin
- HRP2
- Plasmodium falciparum antigen histidine rich protein 2
- HZ
- Health Zone
- iCCM
- integrated Community Case Management
- IQR
- Interquartile Range
- ITT
- Intention-to-Treat
- mRDT
- malaria Rapid Diagnostic Test
- NA
- Not Applicable
- ODK
- Open Data Kit platform
- OR
- Odds Ratio
- PHC
- Primary Health Facility
- pLDH
- Plasmodium lactate dehydrogenase
- PSS
- Patient Surveillance System
- RAS
- Rectal Artesunate
- RHF
- Referral Health Facility
- SD
- Standard deviation
- Swiss TPH
- Swiss Tropical and Public Health Institute
- UNICEF
- United Nations Children’s Fund
- WHO
- World Health Organization
